Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
ABSTRACT Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS receiving mainly novel treatments (between 2006 and 2021...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Cancer Medicine |
| Online Access: | https://doi.org/10.1002/cam4.70266 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850119139238084608 |
|---|---|
| author | K. Mancuso R. Mina S. Rocchi E. Antonioli M. T. Petrucci F. Fazio A. Gozzetti M. Salvini C. S. Cartia G. Bertuglia F. Patriarca A. B. Dalla Palma S. Barbato G. De Cicco F. Bigi E. Favero P. Tacchetti L. Pantani I. Rizzello M. Puppi M. Talarico V. Solli A. Kanapari M. Cavo E. Zamagni |
| author_facet | K. Mancuso R. Mina S. Rocchi E. Antonioli M. T. Petrucci F. Fazio A. Gozzetti M. Salvini C. S. Cartia G. Bertuglia F. Patriarca A. B. Dalla Palma S. Barbato G. De Cicco F. Bigi E. Favero P. Tacchetti L. Pantani I. Rizzello M. Puppi M. Talarico V. Solli A. Kanapari M. Cavo E. Zamagni |
| author_sort | K. Mancuso |
| collection | DOAJ |
| description | ABSTRACT Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS receiving mainly novel treatments (between 2006 and 2021) in eight Italian centres. Based on renal biopsy, patients were divided into two subgroups: AL amyloidosis (70%, n = 42) and other‐MGRS (30%, n = 18). Results Baseline characteristics follow typical manifestations of MGRS disorders in terms of small clonal burden, laboratory and clinical features. More patients with AL amyloidosis had monotypic lambda light‐chain disease, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min and nephrotic proteinuria than other‐MGRS group. The most widely used drug was bortezomib, and about one‐third of patients underwent ASCT. Overall response rate was 86% with no differences in the two subgroups. However, high‐quality hematologic responses ≥very good partial response (VGPR) were greater in AL amyloidosis than in other‐MGRS group (67% vs 28%, p = 0.015). The depth of haematological response influenced renal response, obtained in 32 (59%) of evaluable patients, similarly in the subgroups. Indeed, 75% patients with ≥ VGPR (p = 0.049) and none with stable disease (p ≤ 0.001) obtained a renal response. No association between renal response and histotypes (p = 0.9) or type of first‐line therapy (p = 0.3) was found. At a median follow‐up of 54.4 months (IQR 24.8–102.8), median progression‐free survival (PFS) was 100.1 months (95% CI 34.9–NR), and median overall survival not reached (95% CI 129.8–NR). No significant difference emerged between the two groups in terms of survival outcomes. Achieving ≥ VGPR was confirmed as the main independent predictor of prolonged PFS in the general population (HR = 0.29, p = 0.023) and AL amyloidosis group (HR 0.23; p = 0.023). Preserved renal function at diagnosis was predictive of improved PFS in the AL amyloidosis group (eGFR ≥ 60 mL/min: HR = 0.003; p = 0.018; eGFR 30–60 mL/min: HR = 0.04, p = 0.046). Conclusion Further research is warranted to develop standardised response criteria and treatment strategies to improve MGRS management. |
| format | Article |
| id | doaj-art-0ce5afe23e09445b8e48ac9c3fd5af9d |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0ce5afe23e09445b8e48ac9c3fd5af9d2025-08-20T02:35:41ZengWileyCancer Medicine2045-76342024-11-011322n/an/a10.1002/cam4.70266Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective StudyK. Mancuso0R. Mina1S. Rocchi2E. Antonioli3M. T. Petrucci4F. Fazio5A. Gozzetti6M. Salvini7C. S. Cartia8G. Bertuglia9F. Patriarca10A. B. Dalla Palma11S. Barbato12G. De Cicco13F. Bigi14E. Favero15P. Tacchetti16L. Pantani17I. Rizzello18M. Puppi19M. Talarico20V. Solli21A. Kanapari22M. Cavo23E. Zamagni24IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyMyeloma Unit, Division of Hematology University of Turin and Azienda Ospedaliero‐Universitaria (AOU) Città della Salute e della Scienza di Torino Torino ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyHematology Department Careggi Hospital Florence ItalyHematology–Azienda Policlinico Umberto I‐Department of Translational and Precision Medicine–Sapienza, University of Rome Roma ItalyHematology–Azienda Policlinico Umberto I‐Department of Translational and Precision Medicine–Sapienza, University of Rome Roma ItalyDepartment of Medical Science, Surgery and Neuroscience, Hematology University of Siena Siena ItalyUOC Ematologia, ASST Sette Laghi Ospedale di Circolo e Fondazione Macchi Varese ItalyDivision of Hematology Fondazione IRCCS Policlinico San Matteo Pavia ItalyMyeloma Unit, Division of Hematology University of Turin and Azienda Ospedaliero‐Universitaria (AOU) Città della Salute e della Scienza di Torino Torino ItalyClinica Ematologica, Azienda Sanitaria Universitaria Friuli Centrale, Dipartimento di Medicina Università di Udine Udine ItalyHematology and BMT Unit Azienda Ospedaliero‐Universitaria di Parma Parma ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyDipartimento di Scienze Mediche e Chirurgiche Università di Bologna Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyIRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna ItalyABSTRACT Introduction MGRS are new rare clinical entities, whose recognition and optimal management is evolving. Methods To implement real‐life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy‐proven MGRS receiving mainly novel treatments (between 2006 and 2021) in eight Italian centres. Based on renal biopsy, patients were divided into two subgroups: AL amyloidosis (70%, n = 42) and other‐MGRS (30%, n = 18). Results Baseline characteristics follow typical manifestations of MGRS disorders in terms of small clonal burden, laboratory and clinical features. More patients with AL amyloidosis had monotypic lambda light‐chain disease, estimated glomerular filtration rate (eGFR) ≥ 60 mL/min and nephrotic proteinuria than other‐MGRS group. The most widely used drug was bortezomib, and about one‐third of patients underwent ASCT. Overall response rate was 86% with no differences in the two subgroups. However, high‐quality hematologic responses ≥very good partial response (VGPR) were greater in AL amyloidosis than in other‐MGRS group (67% vs 28%, p = 0.015). The depth of haematological response influenced renal response, obtained in 32 (59%) of evaluable patients, similarly in the subgroups. Indeed, 75% patients with ≥ VGPR (p = 0.049) and none with stable disease (p ≤ 0.001) obtained a renal response. No association between renal response and histotypes (p = 0.9) or type of first‐line therapy (p = 0.3) was found. At a median follow‐up of 54.4 months (IQR 24.8–102.8), median progression‐free survival (PFS) was 100.1 months (95% CI 34.9–NR), and median overall survival not reached (95% CI 129.8–NR). No significant difference emerged between the two groups in terms of survival outcomes. Achieving ≥ VGPR was confirmed as the main independent predictor of prolonged PFS in the general population (HR = 0.29, p = 0.023) and AL amyloidosis group (HR 0.23; p = 0.023). Preserved renal function at diagnosis was predictive of improved PFS in the AL amyloidosis group (eGFR ≥ 60 mL/min: HR = 0.003; p = 0.018; eGFR 30–60 mL/min: HR = 0.04, p = 0.046). Conclusion Further research is warranted to develop standardised response criteria and treatment strategies to improve MGRS management.https://doi.org/10.1002/cam4.70266 |
| spellingShingle | K. Mancuso R. Mina S. Rocchi E. Antonioli M. T. Petrucci F. Fazio A. Gozzetti M. Salvini C. S. Cartia G. Bertuglia F. Patriarca A. B. Dalla Palma S. Barbato G. De Cicco F. Bigi E. Favero P. Tacchetti L. Pantani I. Rizzello M. Puppi M. Talarico V. Solli A. Kanapari M. Cavo E. Zamagni Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study Cancer Medicine |
| title | Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study |
| title_full | Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study |
| title_fullStr | Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study |
| title_full_unstemmed | Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study |
| title_short | Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study |
| title_sort | clinical presentation and long term survival outcomes of patients with monoclonal gammopathy of renal significance mgrs a multicenter retrospective study |
| url | https://doi.org/10.1002/cam4.70266 |
| work_keys_str_mv | AT kmancuso clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT rmina clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT srocchi clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT eantonioli clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT mtpetrucci clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT ffazio clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT agozzetti clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT msalvini clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT cscartia clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT gbertuglia clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT fpatriarca clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT abdallapalma clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT sbarbato clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT gdecicco clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT fbigi clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT efavero clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT ptacchetti clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT lpantani clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT irizzello clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT mpuppi clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT mtalarico clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT vsolli clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT akanapari clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT mcavo clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy AT ezamagni clinicalpresentationandlongtermsurvivaloutcomesofpatientswithmonoclonalgammopathyofrenalsignificancemgrsamulticenterretrospectivestudy |